Last $2.68 USD
Change Today +0.02 / 0.75%
Volume 3.9M
CTIC On Other Exchanges
Symbol
Exchange
BrsaItaliana
NASDAQ CM
Frankfurt
As of 8:10 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

cti biopharma corp (CTIC) Snapshot

Open
$2.66
Previous Close
$2.66
Day High
$2.84
Day Low
$2.57
52 Week High
01/21/14 - $4.25
52 Week Low
09/23/13 - $1.37
Market Cap
402.4M
Average Volume 10 Days
1.9M
EPS TTM
$-0.51
Shares Outstanding
150.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CTI BIOPHARMA CORP (CTIC)

Related News

No related news articles were found.

cti biopharma corp (CTIC) Related Businessweek News

No Related Businessweek News Found

cti biopharma corp (CTIC) Details

CTI BioPharma Corp., a biopharmaceutical company, is engaged in the acquisition, development, and commercialization of treatments for cancer. It primarily focuses on the commercialization of PIXUVRI, an aza-anthracenedione derivative, which is in phase III clinical trials for the treatment of multiply relapsed or refractory aggressive non-Hodgkin lymphoma in the European Union. The company is also developing Pacritinib, an oral inhibitor of Janus Kinase 2 and FMS-like tyrosine kinase, which is in phase III clinical trials for the treatment of myelofibrosis; and is in phase II clinical trial for treatment of relapsed acute myeloid leukemia. In addition, it is developing Tosedostat, an oral aminopeptidase inhibitor that is in phase II clinical trials for the treatment of acute myeloid leukemia; and is in phase II clinical trials for the treatment of acute myeloid leukemia/myelodysplastic syndrome. Further, the company is developing Opaxio, a chemotherapeutic agent that is in phase III clinical trials for the treatment of ovarian cancer; in phase II clinical trials for the treatment of malignant brain cancer; and is in phase II clinical trials for the treatment of head and neck cancer. Additionally, it is developing Brostallicin, which is in phase II clinical trials for the treatment of triple-negative breast cancer. The company has a license and co-development agreement with Chroma Therapeutics, Ltd. to develop and commercialize Tosedostat in North, Central, and South America, or the licensed territory; and a development, commercialization, and license agreement with Baxter International Inc., Baxter Healthcare Corporation, and Baxter Healthcare SA to develop and commercialize Pacritinib worldwide. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was founded in 1991 and is headquartered in Seattle, Washington.

111 Employees
Last Reported Date: 03/4/14
Founded in 1991

cti biopharma corp (CTIC) Top Compensated Officers

Principal Founder, Chief Executive Officer, P...
Total Annual Compensation: $1.3M
Co-Founder, Principal Financial Officer, Prin...
Total Annual Compensation: $553.5K
Co-Founder, Chief Compliance Officer, Interim...
Total Annual Compensation: $551.0K
Executive Vice President of Corporate Develop...
Total Annual Compensation: $585.0K
Compensation as of Fiscal Year 2013.

cti biopharma corp (CTIC) Key Developments

CTI BioPharma Corp. - Special Call

To discuss the collaboration agreement with Servier for development and commercialization of PIXVURI

CTI BioPharma Corp. and Servier Announce Exclusive License and Collaboration Agreement to Develop and Commercialize PIXUVRI(R)

CTI BioPharma Corp. and Servier jointly announced that they have entered into an exclusive license and collaboration agreement to develop and commercialize PIXUVRI(R) (pixantrone) in a transaction valued at up to EUR 103.0 million (approximately $133.5 million) if all milestones are achieved. Under the agreement, CTI retains full commercialization rights for PIXUVRI in Austria, Denmark, Finland, Germany, Israel, Norway, Sweden, Turkey, the United Kingdom and the U.S., with Servier having exclusive rights to commercialize PIXUVRI in all other countries. PIXUVRI is conditionally approved in the European Union for patients with aggressive B-cell non-Hodgkin lymphoma (NHL) who failed two or three prior lines of therapy. PIXUVRI is the first monotherapy treatment option for this patient group and the only therapy licensed for third and fourth line use in aggressive B-cell NHL patients, which includes diffuse large B-cell lymphoma (DLBCL). As of this announcement, PIXUVRI was available in 11 countries and has achieved reimbursement decisions under varying conditions in England/Wales, Italy, France, Germany and the Netherlands. Under the terms of the agreement, CTI will receive an upfront payment of EUR 14 million (approximately $18.1 million) and is eligible to receive additional sales, clinical and regulatory milestone payments, as well as royalties on sales, such royalty payments being subject to certain reductions.

CTI BioPharma Corp. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; provides earnings guidance for the

CTI BioPharma Corp. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company's total revenues were $1,343,000 compared to $306,000 a year ago. The revenues in the second quarter 2014 were primarily attributable to net product sales of PIXUVRI. CTI sells PIXUVRI directly to health care providers through a product dedicated contract sales force and through a limited number of wholesale distributors in the E.U. Loss from operations was $26,668,000 compared to $17,852,000 a year ago. Net loss was $27,399,000 compared to $18,011,000 a year ago. Basic and diluted net loss per common share was $0.19 compared to $0.17 a year ago. As adjusted - loss from operations was $21,312,000 compared to $15,884,000 a year ago. For the six months, the company's total revenues were $2,754,000 compared to $1,432,000 a year ago. Loss from operations was $54,331,000 compared to $36,374,000 a year ago. Net loss was $56,401,000 compared to $37,395,000 a year ago. Basic and diluted net loss per common share was $0.39 compared to $0.35 a year ago. As adjusted - loss from operations was $41,146,000 compared to $31,978,000 a year ago. The increase in GAAP operating loss primarily related to the ongoing PERSIST-1 and PERSIST-2 Phase 3 clinical trials of pacritinib and included $5.4 million and $13.2 million of non-cash share-based compensation expense for the second quarter and first six months of 2014, respectively, compared to $2.0 million and $4.4 million for the same periods in 2013. The company continues to expect that non-GAAP operating loss for 2014 will be approximately $45 million to $50 million, which excludes non-cash share-based compensation expense.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CTIC:US $2.68 USD +0.02

CTIC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Array BioPharma Inc $3.76 USD -0.03
Cytokinetics Inc $4.14 USD +0.28
Exelixis Inc $1.70 USD -0.02
Progenics Pharmaceuticals Inc $5.08 USD -0.14
Rigel Pharmaceuticals Inc $2.18 USD -0.05
View Industry Companies
 

Industry Analysis

CTIC

Industry Average

Valuation CTIC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 10.8x
Price/Book 41.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 9.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CTI BIOPHARMA CORP, please visit www.ctibiopharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.